These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25511594)

  • 1. [Efficacy of tigecycline in treating severe infections of patients with hematological diseases].
    Wu Y; Hu Z; Xing L; Wang H; Liu H; Guan J; Fu R; Li L; Wang G; Song J; Qu W; Wang X; Shao Q; Yu H; Wang Y; Li L; Gao S; Shao Z
    Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(34):2669-72. PubMed ID: 25511594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
    Brust K; Evans A; Plemmons R
    J Antimicrob Chemother; 2014 Oct; 69(10):2606-10. PubMed ID: 24879669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F; Arslan H; Azap OK; Senger SS; Başaran O; Karaman SO; Haberal M
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P; Finch R
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.
    Anthony KB; Fishman NO; Linkin DR; Gasink LB; Edelstein PH; Lautenbach E
    Clin Infect Dis; 2008 Feb; 46(4):567-70. PubMed ID: 18199038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence and features of pathogenic bacteria in the department of hematology without bone marrow transplantation in Peking Union Medical College Hospital from 2010 to 2012].
    Wnag L; Yang C; Zhang Q; Han B; Zhuang JJ; Chen M; Zou N; Li J; Duan MH; Zhang W; Zhu TN; Xu Y; Wang SJ; Zhou DB; Zhao YQ; Zhang H; Wang P; Xu YC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Aug; 36(4):439-45. PubMed ID: 25176215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.